Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Apr 23;286(6374):1309-12.
doi: 10.1136/bmj.286.6374.1309.

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer

J H Waxman, J A Wass, W F Hendry, H N Whitfield, G M Besser, J S Malpas, R T Oliver

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer

J H Waxman et al. Br Med J (Clin Res Ed). .

Abstract

Repeated administration of long acting analogues of gonadotrophin releasing hormone diminishes gonadal function and in men decreases testosterone concentrations; for this reason the effect of the analogue buserelin was studied in prostatic carcinoma. Twelve consecutive patients with newly diagnosed locally advanced or metastatic carcinoma of the prostate were treated. Each patient received intranasal buserelin in divided dosages of either 600 or 1000 micrograms daily. Suppression of the gonadotrophins and testosterone occurred in all patients. Objective and subjective signs of regression of disease were seen in nine patients. Buserelin offers an effective treatment of metastatic prostatic cancer without the side effects and cardiovascular risks associated with oestrogen treatment.

PubMed Disclaimer

References

    1. J Clin Endocrinol Metab. 1969 Aug;29(8):1046-50 - PubMed
    1. J Clin Endocrinol Metab. 1982 May;54(5):1081-3 - PubMed
    1. Br J Urol. 1975 Feb;47(1):1-12 - PubMed
    1. Neuroendocrinology. 1977;24(3-4):195-207 - PubMed
    1. Science. 1978 Nov 10;202(4368):631-3 - PubMed

LinkOut - more resources